The immune checkpoint inhibitor market is transforming oncology by unleashing the body’s own immune system to fight cancer. These drugs block proteins like PD-1, PD-L1, and CTLA-4 that normally keep immune responses in check, allowing T-cells to recognize and destroy tumor cells more effectively. With approvals across multiple cancer types and growing use in combination regimens,...